With Gattex Approval, NPS Joins Pharma’s Commercial Ranks
This article was originally published in The Pink Sheet Daily
Executive Summary
NPS Pharmaceuticals will launch Gattex for the long-term treatment of short bowel syndrome, an ultra-orphan indication, with an ultra-orphan price tag to match: $295,000 per year.